GLP-1 receptor agonists (semaglutide, liraglutide) and AOD-9604 represent two fundamentally different approaches to peptide-based weight loss. Understanding these differences is essential for selecting the right compound — or the right combination — for a specific patient's metabolic profile and weight loss goals.
Central vs. Peripheral Mechanism
GLP-1 receptor agonists work primarily through central mechanisms — they reduce appetite by activating satiety centers in the hypothalamus, delaying gastric emptying, and reducing the reward value of food. The weight loss is primarily driven by reduced caloric intake. AOD-9604, by contrast, works peripherally — it directly stimulates lipolysis in adipose tissue through beta-3 adrenergic receptor activation, increasing fat oxidation independent of caloric intake.
Clinical Outcomes: What to Expect
GLP-1 receptor agonists produce larger absolute weight loss (15-17% in STEP trials) because they address the primary driver of obesity — excess caloric intake. AOD-9604 produces more modest weight loss (5-8% in clinical trials) but specifically targets fat mass with preservation of lean mass — making it valuable for body composition optimization even in individuals who are not significantly overweight.
The Combination Approach
For patients with significant obesity and metabolic syndrome, GLP-1 receptor agonists are the primary intervention. AOD-9604 can be added as an adjunct to specifically target visceral and abdominal fat, which may not be fully addressed by appetite suppression alone. The combination addresses both caloric intake (GLP-1) and fat metabolism (AOD-9604) simultaneously.